Alkem Laboratories

Gross Profit Margin climbs from 65.3% in Q1 FY26 to 67.9% in Q1 FY27 — confirming strong pricing power across the portfolio.

PAT Margin falls from 19.7% in Q1 FY26 to 13.9% in Q1 FY27 — indicating ongoing profit margin pressure despite revenue recovery.

Market Capitalization grows from ₹590,457 Cr in Q1 FY26 to ₹665,894 Cr in Q1 FY27 — reflecting sustained investor confidence.

Promoter Shareholding declines from 53.0% in Q1 FY26 to 49.7% in Q1 FY27 — reflecting gradual stake dilution over the period.

Net Cash increases from ₹48.7 Cr in Q1 FY26 to ₹57.64 Cr in Q1 FY27 — building a robust liquidity buffer for future investments.

US Business Sales cool from ₹7,681 Cr in Q4 FY26 to ₹7,439 Cr in Q1 FY27 — signaling a temporary normalization in key export markets.

Non-US Business Sales expand from ₹3,556 Cr in Q1 FY26 to ₹4,785 Cr in Q1 FY27 — driving steady international diversification.

Respiratory Market Share slips from 1.6% in Q2 FY26 to 1.5% in Q1 FY27 — indicating minor competitive erosion in the segment.

Institutional Shareholding rises from 30.9% in Q1 FY26 to 33.1% in Q1 FY27 — signaling growing fund trust in long-term execution.

ANDA Tentative Approvals drop from 2 in Q1 FY26 to 1 in Q1 FY27 — pointing to a slower regulatory pipeline pace for new launches.